Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. EXEL
stocks logo

EXEL

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
609.25M
+7.5%
0.644
+34.23%
624.23M
+12.38%
0.728
+32.42%
641.12M
+12.82%
0.757
+16.41%
Estimates Revision
The market is revising Upward the revenue expectations for Exelixis, Inc. (EXEL) for FY2025, with the revenue forecasts being adjusted by 0.64% over the past three months. During the same period, the stock price has changed by 17.13%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.64%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+5.93%
In Past 3 Month
Stock Price
Go Up
up Image
+17.13%
In Past 3 Month
Wall Street analysts forecast EXEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EXEL is 45.33 USD with a low forecast of 30.00 USD and a high forecast of 56.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Analyst Rating
Wall Street analysts forecast EXEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EXEL is 45.33 USD with a low forecast of 30.00 USD and a high forecast of 56.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
8 Hold
0 Sell
Moderate Buy
Current: 44.370
sliders
Low
30.00
Averages
45.33
High
56.00
Current: 44.370
sliders
Low
30.00
Averages
45.33
High
56.00
Wolfe Research
Kalpit Patel
Peer Perform
initiated
2025-11-17
Reason
Wolfe Research
Kalpit Patel
Price Target
2025-11-17
initiated
Peer Perform
Reason
Wolfe Research analyst Kalpit Patel initiated coverage of Exelixis with a Peer Perform rating and no price target. Zanzalintinib is unlikely to fully replenish cabozantinib's potential lost revenues, the analyst tells investors.
Morgan Stanley
Overweight
maintain
$44 -> $45
2025-11-07
Reason
Morgan Stanley
Price Target
$44 -> $45
2025-11-07
maintain
Overweight
Reason
Morgan Stanley raised the firm's price target on Exelixis to $45 from $44 and keeps an Overweight rating on the shares. Cabo continues to demonstrate sustained demand and the NET launch progresses well with roughly $100M expected in contribution to 2025 net product revenue, the analyst tells investors in a research note. The firm added the company expects to submit the NDA in previously treated mCRC in December 2025, pending the U.S. government re-opening.
UBS
Neutral
maintain
$35 -> $40
2025-11-06
Reason
UBS
Price Target
$35 -> $40
2025-11-06
maintain
Neutral
Reason
UBS raised the firm's price target on Exelixis to $40 from $35 and keeps a Neutral rating on the shares.
Stifel
Stephen Willey
Hold
maintain
$41 -> $43
2025-11-05
Reason
Stifel
Stephen Willey
Price Target
$41 -> $43
2025-11-05
maintain
Hold
Reason
Stifel analyst Stephen Willey raised the firm's price target on Exelixis to $43 from $41 and keeps a Hold rating on the shares following a Q3 earnings announcement and corporate update that the firm says had "no significant surprises.
TD Cowen
NULL -> Buy
maintain
$44 -> $51
2025-11-05
Reason
TD Cowen
Price Target
$44 -> $51
2025-11-05
maintain
NULL -> Buy
Reason
TD Cowen raised the firm's price target on Exelixis to $51 from $44 and keeps a Buy rating on the shares. The firm updated its model following Q3 results.
H.C. Wainwright
Robert Burns
maintain
$46 -> $49
2025-11-05
Reason
H.C. Wainwright
Robert Burns
Price Target
$46 -> $49
2025-11-05
maintain
Reason
H.C. Wainwright analyst Robert Burns raised the firm's price target on Exelixis to $49 from $46 and keeps a Buy rating on the shares following the Q3 report. The firm sees the key value driver for the shares as sentiment on the commercial future for zanzalintinib across various tumor types.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Exelixis Inc (EXEL.O) is 14.82, compared to its 5-year average forward P/E of 27.85. For a more detailed relative valuation and DCF analysis to assess Exelixis Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
27.85
Current PE
14.82
Overvalued PE
41.62
Undervalued PE
14.07

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
17.19
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
27.15
Undervalued EV/EBITDA
7.23

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.95
Current PS
0.00
Overvalued PS
4.68
Undervalued PS
3.21
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 828.52% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 828.52% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

EXEL News & Events

Events Timeline

(ET)
2025-11-04
16:30:17
Exelixis Announces Q3 Adjusted EPS of 81 Cents, Exceeding Consensus Estimate of 67 Cents
select
2025-11-04
16:29:36
Exelixis Announces Q3 Earnings Per Share of 78 Cents, Exceeding Consensus Estimate of 67 Cents
select
2025-10-20 (ET)
2025-10-20
12:00:06
Exelixis Experiences a 12.8% Decline
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
12-04Newsfilter
Exelixis to Host 2025 R&D Day Focusing on Next-Gen Oncology Strategies
  • Event Announcement: Exelixis will host its virtual event, Exelixis 2025 R&D Day, on December 10, 2025, from 1:00 PM to 3:30 PM EST, where the company will review its R&D progress and outline strategies for future oncology franchises, aiming to elevate care standards for cancer patients and generate long-term shareholder value.
  • Strategic Focus: The event will highlight Exelixis' ongoing innovations in oncology, particularly through its clinically differentiated pipeline targeting a growing range of tumor types, addressing the increasing market demand for effective cancer treatments.
  • Investor Engagement: Participants are encouraged to register in advance to ensure timely access on the day of the event, with the content available for one year on the company website and dedicated event page, enhancing transparency and information accessibility for investors and the public.
  • Company Vision: Exelixis is committed to transforming cancer treatment through its flagship product CABOMETYX® and other investigational programs, helping more patients recover and live longer, showcasing the company's ambition and responsibility in the oncology field.
[object Object]
Preview
5.0
11-28NASDAQ.COM
Insider Buying Update for Friday, November 28: EXEL, ONMD

  • Exelixis Insider Purchase: Director David Edward Johnson bought 27,532 shares of EXEL at $43.12 each, totaling $1.19M, marking his first purchase in a year. EXEL's stock was up about 0.7% on Friday, reaching a high of $44.85.

  • OneMedNet Insider Purchase: Director Thomas Kosasa purchased 1,879,871 shares of OneMedNet for $1.05M at $0.56 each. The stock surged 45.1% on Friday, with Kosasa's investment up approximately 301.2% at its peak, reaching $2.24.

[object Object]
Preview
6.0
11-07Benzinga
UBS Keeps Neutral Rating on Exelixis and Increases Price Target to $40

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, indicating a robust network for sharing market intelligence.

  • Market Winning Tools: Benzinga Pro is designed to equip traders with the tools and information necessary to succeed in the markets daily.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Exelixis Inc (EXEL) stock price today?

The current price of EXEL is 44.37 USD — it has increased 0.82 % in the last trading day.

arrow icon

What is Exelixis Inc (EXEL)'s business?

Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.

arrow icon

What is the price predicton of EXEL Stock?

Wall Street analysts forecast EXEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EXEL is 45.33 USD with a low forecast of 30.00 USD and a high forecast of 56.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Exelixis Inc (EXEL)'s revenue for the last quarter?

Exelixis Inc revenue for the last quarter amounts to 597.76M USD, increased 10.79 % YoY.

arrow icon

What is Exelixis Inc (EXEL)'s earnings per share (EPS) for the last quarter?

Exelixis Inc. EPS for the last quarter amounts to 0.69 USD, increased 72.50 % YoY.

arrow icon

What changes have occurred in the market's expectations for Exelixis Inc (EXEL)'s fundamentals?

The market is revising Upward the revenue expectations for Exelixis, Inc. (EXEL) for FY2025, with the revenue forecasts being adjusted by 0.64% over the past three months. During the same period, the stock price has changed by 17.13%.
arrow icon

How many employees does Exelixis Inc (EXEL). have?

Exelixis Inc (EXEL) has 1147 emplpoyees as of December 05 2025.

arrow icon

What is Exelixis Inc (EXEL) market cap?

Today EXEL has the market capitalization of 11.89B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free